Apellis Capital Lease Obligations from 2010 to 2025
| APLS Stock | USD 24.28 0.49 2.06% |
Capital Lease Obligations | First Reported 2019-03-31 | Previous Quarter 18.2 M | Current Value 17 M | Quarterly Volatility 4.4 M |
Check Apellis Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Apellis Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Interest Expense of 42.4 M or Selling General Administrative of 526.1 M, as well as many indicators such as Price To Sales Ratio of 5.29, Dividend Yield of 0.0 or PTB Ratio of 18.84. Apellis financial statements analysis is a perfect complement when working with Apellis Pharmaceuticals Valuation or Volatility modules.
Apellis | Capital Lease Obligations |
Latest Apellis Pharmaceuticals' Capital Lease Obligations Growth Pattern
Below is the plot of the Capital Lease Obligations of Apellis Pharmaceuticals over the last few years. Apellis Pharmaceuticals capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Apellis Pharmaceuticals asset purchases. For example, Apellis Pharmaceuticals can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Apellis Pharmaceuticals control over an asset for a big portion of its life. It is the total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee. Apellis Pharmaceuticals' Capital Lease Obligations historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Apellis Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Capital Lease Obligations | 10 Years Trend |
|
Capital Lease Obligations |
| Timeline |
Apellis Capital Lease Obligations Regression Statistics
| Arithmetic Mean | 16,227,411 | |
| Geometric Mean | 16,057,835 | |
| Coefficient Of Variation | 15.50 | |
| Mean Deviation | 2,201,795 | |
| Median | 14,465,975 | |
| Standard Deviation | 2,515,077 | |
| Sample Variance | 6.3T | |
| Range | 6.7M | |
| R-Value | 0.76 | |
| Mean Square Error | 2.9T | |
| R-Squared | 0.58 | |
| Significance | 0.0006 | |
| Slope | 401,156 | |
| Total Sum of Squares | 94.9T |
Apellis Capital Lease Obligations History
About Apellis Pharmaceuticals Financial Statements
Apellis Pharmaceuticals shareholders use historical fundamental indicators, such as Capital Lease Obligations, to determine how well the company is positioned to perform in the future. Although Apellis Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Apellis Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Apellis Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Capital Lease Obligations | 17 M | 20.1 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.